Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE6.6500
- TODAY'S CHANGE (%)-0.0600 (-0.8942%)
- Bid / Lots6.5300/ 1
- Ask / Lots7.0400/ 4
- Open / Previous Close6.7100 / 6.7100
- Day Range
- 52 Week Range
- Volume193,983
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 2832 | 6.8 |
| 09:36 ET | 515 | 6.87 |
| 09:38 ET | 3457 | 6.7248 |
| 09:39 ET | 2100 | 6.8473 |
| 09:41 ET | 100 | 6.795 |
| 09:48 ET | 228 | 6.8042 |
| 09:50 ET | 200 | 6.8338 |
| 09:54 ET | 1200 | 6.79 |
| 09:56 ET | 200 | 6.761 |
| 09:57 ET | 300 | 6.71 |
| 09:59 ET | 198 | 6.6806 |
| 10:01 ET | 9279 | 6.6158 |
| 10:03 ET | 1930 | 6.62 |
| 10:06 ET | 7337 | 6.59 |
| 10:08 ET | 12608 | 6.46 |
| 10:10 ET | 5018 | 6.55 |
| 10:12 ET | 3912 | 6.51 |
| 10:14 ET | 7191 | 6.485 |
| 10:15 ET | 1200 | 6.535 |
| 10:17 ET | 100 | 6.58 |
| 10:19 ET | 640 | 6.63 |
| 10:21 ET | 400 | 6.6656 |
| 10:24 ET | 5667 | 6.63 |
| 10:26 ET | 9008 | 6.55 |
| 10:28 ET | 1288 | 6.58 |
| 10:32 ET | 600 | 6.5844 |
| 10:33 ET | 726 | 6.52 |
| 10:37 ET | 10612 | 6.5 |
| 10:39 ET | 2300 | 6.47 |
| 10:42 ET | 162 | 6.4777 |
| 10:44 ET | 1208 | 6.5 |
| 10:46 ET | 900 | 6.4701 |
| 10:48 ET | 1628 | 6.52 |
| 10:53 ET | 300 | 6.4801 |
| 10:55 ET | 2802 | 6.5199 |
| 10:57 ET | 293 | 6.53 |
| 11:00 ET | 151 | 6.5347 |
| 11:02 ET | 1300 | 6.53 |
| 11:08 ET | 300 | 6.585 |
| 11:11 ET | 2800 | 6.6257 |
| 11:20 ET | 250 | 6.615 |
| 11:22 ET | 300 | 6.57 |
| 11:24 ET | 200 | 6.5401 |
| 11:27 ET | 100 | 6.54 |
| 11:36 ET | 527 | 6.56 |
| 11:42 ET | 100 | 6.575 |
| 11:44 ET | 300 | 6.59 |
| 11:45 ET | 3400 | 6.56 |
| 11:56 ET | 100 | 6.575 |
| 12:02 ET | 400 | 6.5674 |
| 12:14 ET | 100 | 6.57 |
| 12:20 ET | 543 | 6.61 |
| 12:30 ET | 113 | 6.56 |
| 12:34 ET | 400 | 6.5336 |
| 12:38 ET | 211 | 6.5744 |
| 12:39 ET | 400 | 6.5523 |
| 12:50 ET | 4014 | 6.58 |
| 12:56 ET | 100 | 6.575 |
| 12:59 ET | 100 | 6.58 |
| 01:24 ET | 100 | 6.5701 |
| 01:30 ET | 900 | 6.5899 |
| 01:39 ET | 1300 | 6.55 |
| 01:42 ET | 447 | 6.58 |
| 01:44 ET | 650 | 6.6149 |
| 01:55 ET | 1800 | 6.55 |
| 01:57 ET | 1000 | 6.5759 |
| 02:08 ET | 200 | 6.55 |
| 02:11 ET | 262 | 6.57 |
| 02:18 ET | 100 | 6.5501 |
| 02:26 ET | 200 | 6.57 |
| 02:31 ET | 400 | 6.57 |
| 02:36 ET | 100 | 6.58 |
| 02:47 ET | 100 | 6.5756 |
| 02:51 ET | 100 | 6.565 |
| 02:58 ET | 170 | 6.56 |
| 03:00 ET | 100 | 6.56 |
| 03:09 ET | 100 | 6.56 |
| 03:12 ET | 300 | 6.56 |
| 03:23 ET | 700 | 6.565 |
| 03:25 ET | 200 | 6.56 |
| 03:32 ET | 213 | 6.55 |
| 03:34 ET | 100 | 6.56 |
| 03:36 ET | 1535 | 6.56 |
| 03:38 ET | 200 | 6.59 |
| 03:41 ET | 1000 | 6.59 |
| 03:43 ET | 3245 | 6.6 |
| 03:45 ET | 2464 | 6.64 |
| 03:48 ET | 100 | 6.6 |
| 03:50 ET | 1100 | 6.6099 |
| 03:52 ET | 1798 | 6.6 |
| 03:56 ET | 1236 | 6.61 |
| 03:57 ET | 500 | 6.615 |
| 03:59 ET | 28010 | 6.65 |
Yesterday
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting, from 9:00AM ET on Friday Oct 04, 2024 by Dow Jones
9:00AM ET on Friday Oct 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 213.4M | -3.9x | --- |
Black Diamond Therapeutics Inc | 211.9M | -2.4x | --- |
Immutep Ltd | 313.4M | -8.6x | --- |
Pyxis Oncology Inc | 210.4M | -2.8x | --- |
Acrivon Therapeutics Inc | 217.1M | -2.5x | --- |
Omeros Corp | 218.5M | -1.1x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $213.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
